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 Abstract (no more than 200 words) 
 
Despite some promising results, the majority of patients do not benefit from T-cell therapies, as tumors 
prevent T-cells from entering the tumor, shut down their activity, or downregulate key antigens. Due to their 
nature and mechanism of action, oncolytic viruses have features that can help overcome many of the barriers 
currently facing T-cell therapies of solid tumors. This study aims to understand how four different oncolytic 
viruses (adenovirus, vaccinia virus, herpes simplex virus and reovirus) perform in that task. For that purpose, an 
immunocompetent in vivo tumor model featuring adoptive tumor-infiltrating lymphocyte (TIL) therapy was 
used. Tumor growth control (p<0.001) and survival analyses suggest that adenovirus was most effective in 
enabling T-cell therapy. The complete response rate was 62% for TILs+Adenovirus vs 17.5% for TILs+PBS. Of 
note, TIL biodistribution did not explain efficacy differences between viruses. Instead, immunostimulatory 
shifts in the tumor microenvironment mirrored efficacy results. Overall, the use of oncolytic viruses can 
improve the utility of T-cell therapies, and additional virus engineering by arming with transgenes can provide 
further antitumor effects. This phenomenon was seen when an unarmed oncolytic adenovirus was compared 
to Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123). A clinical trial is ongoing, where patients receiving TIL treatment 
also receive TILT-123 (NCT04217473). 
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Introduction 
The fundamental idea of viral infections being beneficial for tumor control has been present for over a hundred 
years now
1
, originating just a few years after viruses were discovered. Already on a theoretical level, it makes 
sense to use those agents to treat cancer as the cellular and molecular characteristics of tumor cells make 
them particularly vulnerable to viral infections. Fast growth and defects in apoptosis and immune mechanisms 
are some of the key flawed mechanisms in cancer cells, making it more difficult for them to stop virus 
infections
2
. In 1949
3
, the first one using a virus as an antitumor therapy was carried out and in the following 
years, other studies using viruses for the treatment of different tumor types were conducted
4-6
. However, the 
overall inconclusive results, influenced by small patient numbers and poor “products” (mainly consisting of wild 
type viruses), reduced the interest of the scientific community in virotherapy of cancer. Later on, technological 
development allowed the refinement of the approach by the engineering of tumor-selective viruses
7
.  
Because the efficacy of single agent virotherapy has generally been suboptimal, immunosuppressive 
chemotherapy has been studied preclinically for its ability to increase direct oncolytic activity
8-12
. When it was 
realized that in humans oncolytic viruses trigger anti-tumor immunity, the approach was radically changed13. 
Instead of aiming at optimal oncolysis, viruses were now being designed to enhance immune activities. The 
first oncolytic virus approved in the United States and Europe
14
, Talimogene laherparepvec (Imlygic®), is a 
Herpes simplex virus engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF). Like 
Talimogene laherparepvec, other oncolytic viruses have also been designed to include immunostimulatory 
gene constructs, such as cytokines, ligands or antagonists
15-17
.  
In the last decade, the T-cell component of the immune system has been drawing attention, as T-cell related 
therapies, such as chimeric antigen receptor T cells (CAR T)
18, 19
, adoptive T-cell therapy with tumor-infiltrating 
lymphocytes (TIL)
20, 21
, adoptive T-cell receptor therapy
22
, and checkpoint inhibitors
23
 emerged as potent tools 
in clinical oncology. These approaches have been used in the clinics with promising results, as they can result in 
long-lasting responses, and in fact, appear to be able to cure a proportion of patients with metastatic cancer. 
Consequently, several products have been approved.  
On the other hand, and especially regarding solid tumors, only a fraction of treated patients benefit from these 
therapies and only in particular indications. Overall response rates are below 10% for CAR T therapy
24
, around 
50% for adoptive T-cell therapy of melanoma
25
 and 0-40% for checkpoint inhibitors
26
. Most commonly, T-cell 
therapies fail because of immunosuppressive conditions in the tumor milieu
27, 28
, the ability of some tumors to 
prevent T-cell infiltration
29, 30
, and antigen loss for those treatments where specific targets were chosen for 
engineered T cells
31
. 
Due to their mechanism of action, oncolytic viruses have been proposed as a valuable tool to overcome T-cell 
therapy limitations
15, 32
, and actually tested by different groups
33, 34
. Their ability to create an 
immunostimulatory signal increases immune cell trafficking towards the tumor
35, 36
, reverses the 
immunosuppressive status of the microenvironment37, 38 and creates de novo adaptive immunity against the 
pool of tumor epitopes released upon oncolysis
39-41
. Taking into account that different viruses have different 
properties, each virus will probably offer distinct therapeutic possibilities. In this study, four different viruses 
representing different families (Adenoviridae, Poxviridae, Herpesviridae, and Reoviridae), widely studied 
clinically, were chosen for study in the context of adoptive T-cell therapy.  
 
Results 
- Selecting treatment dose for different viruses 
The Syrian hamster model was selected to study in vivo efficacy, as it is perhaps the only model permissive for 
the productive replication of all viruses used in the study42-45. The selected tumor model, HapT1 pancreatic 
carcinoma, enables the isolation of tumor infiltrating lymphocytes (TILs) for ex vivo amplification, for use as an 
adoptive cell therapy (ACT)
46
. It was also assessed that the selected virus had oncolytic activity on the cell line 
(Supplementary figure 1) 
For the comparison of adenovirus, vaccinia virus, herpes simplex virus, and reovirus, weight-per-weight 
hamster doses were established based on the maximum tolerated dose used in human trials. At the beginning 
of the project (May 2016), a search for clinical trials investigating the abovementioned viruses was performed, 
and the maximum tolerated dose in humans was identified for each of the viruses (Table 1). Because there was 
no established maximum tolerated dose for an unarmed herpes simplex virus, that of Talimogene 
laherparepvec was selected for this study.
47
 
The dose extrapolation from human maximum tolerated dose to the one used in Syrian hamsters assumes 75 
kg as standard human weight and 0.1 kg as standard Syrian hamster weight. Thus, maximum tolerated doses in 
humans were divided 750 times to achieve with the dose to be used in hamsters. To assess the feasibility of the 
extrapolated doses, ten times higher dose and ten times smaller dose were also tested in vivo (Supplementary 
figure 2). None of the groups treated with 10 times more virus showed better tumor growth control than the 
directly extrapolated dose (presumably because of virus replication decreasing the importance of input dose), 
supporting the rationale for using the extrapolated doses. Using the same units (vp, pfu or TCID50) as had been 
published in human trials avoided the problem of different titering procedures.   
 
- Oncolytic adenovirus has the best antitumor efficacy when used as T-cell therapy enabler 
For the study of the antitumor efficacy of different viruses, HapT1 cells were subcutaneously engrafted in the 
lower right flank of Syrian hamsters. Ten days later, when tumors were palpable and measurable (mean 
volume: 205.63 mm
3
, standard error of the mean: 15.76 mm
3
), those animals were randomized into groups. All 
animals received an adoptive cell graft of ex vivo expanded TILs intraperitoneally at day 0. Depending on the 
group, the animals also received intratumoral virus treatments or PBS as a negative control. Intratumoral 
treatments were administered on days 0, 1, 3 and then once every three days until day 39 (Figure 1A). After 
day 39, animals were not treated, but regular measuring and health checkups were performed. Animals were 
kept alive until their tumor exceeded the allowed tumor dimensions (22 mm for the longest tumor diameter).  
Individual values of normalized tumor volumes are displayed in Figures 1B-F. The only virus that provided a 
significant reduction in tumor volume compared to the effect of adoptive T-cell therapy alone was adenovirus 
(p < 0.001). The group treated with adenovirus also showed significantly better tumor growth control than 
those animals treated with herpes simplex virus (p < 0.001). None of the other viruses were able to provide 
significant tumor growth control compared to the PBS control or other viruses.  
In line with tumor growth control results, the only group that showed significantly increased survival was the 
one treated with adenovirus (Figure 1G), when compared with the herpes simplex virus group (p =0.049). It is 
also relevant to look at the proportion of complete responses by day 250: PBS (17.5%), adenovirus (62.5%), 
vaccinia virus (12.5%), herpes simplex virus (0%), and reovirus (12.5%). There were three times more complete 
responses in the adenovirus group than in the second best group. 
 
- Antitumor memory can be elicited by the use of oncolytic adenovirus and T-cell therapy 
After initial treatment, animals that showed no visible tumors by day 250 were included in a follow-up 
experiment, to investigate if they had gained specific antitumor memory able to reject a new graft of the same 
HapT1 tumors that they were cured from. For that purpose, the same amount of HapT1 cells were engrafted in 
the opposite side of the hamster’s back (upper left flank). At the same time, a different cell line (DDT1-MF2, 
Syrian hamster leiomyosarcoma), for which the animals were naïve to, was engrafted in the upper right flank to 
control the specificity of the antitumor memory. After this tumor rechallenge, the animals did not receive any 
treatment, as the purpose was to study the ability of the previous treatments to generate immunological 
memory. Hamsters that were never exposed to any cancer cell lines and/or treatments served as negative 
control (Figures 2A-B). After tumor engraftment, the animals were followed for 19 days. By that day, DDT1-
MF2 tumors were reaching the regulatory tumor size limit in the majority of the animals. 
As displayed in Figure 2C, all animals (with the exception of the animal from the vaccinia virus group) that 
showed a complete response from the previous treatments had lower tumor volumes on day 19 than naïve 
animals. The animals that had previously received adoptive T-cell therapy and either PBS or reovirus started 
developing the tumors faster in the first days of the experiment, but then showed noticeable partial responses 
by day 19. A much clearer result was observed from the animals previously treated with adoptive T-cell therapy 
and adenovirus, as those animals showed lower average tumor volume than naïve animals as early as by day 8. 
By day 19, 5 out 6 animals in that group showed no visible HapT1 tumor. This result suggests that adenovirus 
was most effective in generating antitumor memory. The animal cured with vaccinia virus and T-cell therapy 
had a larger tumor than naïve animals, but drawing conclusions on just one animal is difficult. There were no 
animals cured with Herpes and thus rechallenge could not be performed.  
DDT1-MF2 tumors took a longer time to start growing visibly, but then they increased their volume 
exponentially (Figure 2D). None of the animals included in the experiment showed protection against this cell 
line, validating the assumption that rechallenged complete responders had antitumor memory against HapT1 
specifically. 
 
- Antitumor efficacy is not directly explained by trafficking of the T-cell graft   
Our next goal was to study the contribution of the transferred T-cell graft to the response and repolarization of 
the immune microenvironment. For that purpose, a new animal experiment was set up, following similar 
conditions as before. The main differences were the length of the study and the primary endpoint: tumors 
were collected 6 days after treatment start, to study the biodistribution of the adoptive T-cells and gene 
expression profiles (Figure 3A). 
To study the biodistribution of the T-cell graft, the cells were labeled with 
111
Indium-oxine. 
111
Indium-oxine is a 
radioactive compound that allows the tracking of cells in vivo with SPECT/CT measurements as well as ex vivo 
radioactivity measurements after organs are collected. At days 0, 1, 3, and 6 tumors were measured with a 
digital caliper (Figure 3B). In addition, tumor volume was determined on day 6 based on CT images and 
validated by correlating with the tumor mass after harvesting (Figure 3C). The in vivo radioactivity 
measurements observed with SPECT/CT were also validated by comparing the values to the radiation 
measured by a gamma counter after tissue harvesting (Figure 3D). A clear correlation between in vivo and ex 
vivo radiation uptake was observed (p < 0.0001). Thus, SPECT/CT measurements can be used reliably when 
evaluating the trafficking of adoptively transferred T-cells in different groups. 
In vivo measurements of the animals were performed approximately 24 (day 1), 72 (day 3) and 144 (day 6) 
hours after the labeled cells were transferred to the animals. A graphic representation of the amount of 
radioactive signal is shown in Figure 3E. For days 1 and 3, there was no statistically significant increase in the 
radioactivity levels, but at day 3 a trend indicating reovirus recruiting  a higher number of radiolabeled T cells in 
tumors was observed. At day 6, a significant increase of radioactivity signals were found in tumors treated with 
reovirus (p =0.028) and with herpes simplex virus (p=0.031) when compared with PBS. On the other hand, the 
vaccinia virus treated group had lower radioactivity signals than any other group (p <0.01). The reovirus treated 
group also showed significantly higher radioactive intensity signals than the adenovirus treated one (p =0.042). 
However, the groups having the highest T-cell trafficking did not match the groups having the best antitumor 
response or immunological memory against the tumors. 
Besides tumors, other tissues including blood, kidney, spleen, and muscle, were analyzed ex vivo to have a 
deeper understanding of the biodistribution of the T-cell graft. In addition, we wanted to assess if any of the 
viruses caused extratumoral accumulation of adoptively transferred T cells (Figure 3F). Kidneys in the 
adenovirus group had lower radioactivity than all the other groups, and the difference was statistically 
significant when compared with vaccinia and herpes simplex virus groups (p <0.05). Also, a considerable 
proportion of the T-cell graft could be found in spleens for all the groups regardless of the treatments. 
 
- Immune repolarization is seen in the groups with the best antitumor responses 
Animals receiving a T-cell transfer might obtain an improved outcome from the therapy, if the tumor 
microenvironment is altered to favor the development and exertion of immune responses against malignant 
cells. To study this hypothesis, tumors collected at day 6 (Figure 3A) were analyzed for gene-expression levels. 
RNA was extracted and studied by a multiplexed immune panel, specifically designed for Syrian hamsters 
(Supplementary table 1). From all the designed probes, only those that passed quality control were included in 
the comparison of expression profiles (Figure 4). Adjusted p values and fold changes are described in 
Supplementary table 2. 
Gene expression profiles after treatment with virotherapy and T-cell therapy showed that the only candidate 
able to induce significant changes in the studied genes was adenovirus. In adenovirus-treated tumors, genes 
related to the following functions were upregulated: production of proinflammatory cytokines (IL1B, TNF, 
GZMM), proinflammatory cytokine receptors (IFNGR1), innate immune system (TLR9, TLR2), myeloid 
stimulatory markers (CD80, CD40), chemokines (CCL3, CCL4), chemokine receptors (CCR1), adaptive immunity 
cell markers (CD4, CD3E) and immune signal mediators (HCK, SYK). This points to a broad immune activity being 
stimulated at the tumor niche, covering a wide range of immune mechanisms. In addition, an upregulation of 
ARG1 (a gene coding for immunosuppressive arginase 1) was also witnessed, possibly indicating a counter-
reaction to immunostimulation.  
The other three viruses studied in this experiment did not produce any significant upregulation in the genes 
included in the panel, although sub-significant gene expression variations were seen in reovirus and herpes 
simplex virus groups (Supplementary table 2). For the tumors treated with vaccinia virus, there were barely any 
gene expression alterations even at a sub-significant level. 
 
- An engineered adenovirus armed with TNFa and IL-2 increases efficacy   
As adenovirus appeared the best candidate to enhance ACT among the studied viruses, we studied differences 
between an unarmed virus and a cytokine-armed virus (Figure 5A). TILT-123 is armed with TNFa and IL-2 
(Ad5/3-E2F-d24-hTNFa-IRES-hIL2)
51, 52
, selected for their ability to boost antitumor activity in the T-cell 
compartment
51
.  
When comparing antitumor efficacy in the experimental set up described in Figure 1A, TILT-123 performed 
better in terms of tumor growth control than the unarmed adenovirus (Adenovirus vs PBS p=3.41x10
-4
. TILT-
123 vs PBS p=1.15x10
-9
) (Figure 5B). Survival data (Figure 5C) shows how the armed version of the virus 
provided better survival for the first 40 days, but after treatment discontinuation, tumor progression led to the 
death of many animals (non-significant difference).  
Complete responders were rechallenged as described before (Figure 2A). Although the number of animals was 
limited (n=2), TILT-123 treated animals showed total rejection, specifically for HapT1 tumors (Figures 5D-E). 
These data seem to indicate improved antitumor efficacy and immunological memory with cytokine-armed 
oncolytic adenovirus over the unarmed adenovirus. 
When studying the impact of the arming device on the trafficking of the adoptive T-cell graft, there was 
statistically significant increased trafficking when compared to mock (p <0.046), in contrast with the unarmed 
adenovirus (Figure 5F).  
We also studied how the arming device affects the tumor’s gene expression profile. When the expression 
patterns of armed and unarmed adenovirus tumors were directly compared, the only genes significantly 
downregulated in TILT-123 treated group were CCL4 (adjusted p value =0.045, Fold change =0.436) and TNF 
(adjusted p value =0.045, Fold change =0.201) (Supplementary figure 3). When comparing the changes induced 
by each of those viruses as opposed to the PBS injection, some of the changes were seen with both viruses 
(IL1B, CD4, CD3E, GZMM), while other genes that were unaffected by the unarmed virus were upregulated 
(IL2RA, PRF1) or downregulated (LBP, IL-10, CCL7, CASP3, CASP8) upon TILT-123 treatment (Figures 5G-H). 
Additionally, several of the upregulated genes with the unarmed virus were not induced with the armed virus 
(CCL4, CCL3, HCK, IFNGR1, CD40, CD80, TLR2, TLR9, CCR1, SYK, ARG1, TNF). 
 
Discussion 
The implementation of immunotherapies such as checkpoint inhibitors and various immune-cell therapy based 
platforms has mediated a therapeutic revolution in oncology. At the same time, there is clear room for 
improvement as the patients responding to immunological treatments are still the minority
26, 53
, with some 
exceptions (e.g. CAR T therapies in some hematological malignancies or anti-PD1 in selected indications). 
Oncolytic viruses offer a rational alternative to solve the limitations of those immunotherapies, but the lack of 
head-to-head comparisons between different virus platforms has slowed optimization of the approach. In 
addition, given major differences in the biology of popular oncolytic viruses, there might be different optimal 
uses for each. For that reason, this study focuses in a direct comparison of some of the most relevant 
candidates in the context of TIL therapy. 
When comparing different therapeutic options, the challenge is to select the optimal dosing for each 
treatment. One possible option is to use the same dose for all of the viruses. For that approach, the first 
limitation is that different viruses are usually titered by different parameters: adenoviruses in viral particles 
(vp), herpes simplex and vaccinia virus in plaque forming units (pfu), and reovirus in median tissue culture 
infectious dose (TCID50). Although these differences could, in theory, be sorted out by assembling a set of 
viruses and measuring their properties, the conversion between units would not be applicable to multiple virus 
batches, thus invalidating references to previous work. Another critical limitation when using the same dose for 
all the viruses is the fact that different viruses have different effects in the host, which is translated into 
different therapeutic windows. Those virus-caused effects occur at various levels, including at the immune 
compartment. For this reason, we narrowed down the comparison of the viruses only in the context of T-cell 
therapies and not going into a deep characterization of the viruses as monotherapies. 
The approach almost universally used in oncology is that drugs are used at their maximum tolerated dose. 
Different oncolytic viruses are used in the clinics at different therapeutic ranges, so taking this information into 
account also helps obtaining more realistic results with regards to safety versus efficacy. In that sense, and 
together with the results showing that the 10-fold increase in dose did not produce stronger antitumor effect, 
we considered that the doses extrapolated weight per weight from the maximum tolerated human dose were 
appropriate. 
Adenovirus emerged as the strongest candidate for enabling adoptive T-cell therapy. Tumors responding to 
treatment within the first 21 days (5/8) did not progress afterwards, and eventually showed complete 
responses. The large amount of complete responders (62.5% of all the animals receiving TILs and adenovirus 
compared to 17.9% of those receiving TILs alone) highlights the potential of adenoviruses to enable T-cell 
antitumor functions. Other viruses did not provide significant improvements in tumor growth control or 
survival. However, some parameters like median survival, were increased when compared with the PBS control 
(108 days for reovirus versus 67 days for PBS, not statistically significant).  
In vaccinia virus, herpes simplex virus and reovirus treated groups, responses to the treatment were observed 
in individual animals, but unlike in the adenovirus group, some of the tumors that shrank to barely palpable 
volume, eventually progressed and reached the maximum tumor dimensions allowed. In this particular 
experiment, the herpes simplex group was the only one that did not show any complete responses. Further 
engineering of the HSV could help to have higher local antigen presentation (ICP47 deletion) and higher local 
immunostimulatory effect (gamma34.5 deletion) in the tumor milieu
54
.  
As oncolytic viruses have a dual mechanism of action (direct oncolysis and immune-mediated antitumor 
response), we wanted to assess what is the immune outcome of each oncolytic virus. For that purpose, animals 
that developed complete responses against pancreatic carcinoma tumors were challenged again with the same 
cell line and left untreated. The only animals that completely rejected the tumors were those belonging to the 
adenovirus treatment group. Eighty percent of the animals once cured by oncolytic adenovirus and TIL therapy 
showed fully protective antitumor-specific memory, while none of the other animals (previously cured with 
TILs alone or in combination with vaccinia virus or reovirus) managed to reject the graft. Other studies focused 
on the systemic effect after the use of oncolytic adenoviruses and T-cell therapies, showing that metastatic 
processes can be avoided
55
 and that uninjected established tumors benefit from the treatment
56
. These results 
enabled us to hypothesize that oncolytic viruses can deliver complete responses by either direct oncolysis or by 
the development of immune-related effects. While the development of adaptive responses against the tumor 
is enhanced by oncolysis
39, 40
, meaning that the variables are not really independent, it is at least theoretically 
possible that some oncolytic viruses deliver antitumor responses mainly by direct oncolysis. This would imply 
that cell lysis by those viruses would not enhance effective generation of antitumor-specific immune 
responses. The dual mechanism of action does not need to be seen from a binary perspective, but to be 
understood in a sense that each virus generates both mechanisms to different extents. Of note, our data 
suggests that there are important differences between viral strains in this regard. 
After observing tumor-specific immune responses, it was interesting for us to understand the contribution of 
the T-cell graft and the overall immune microenvironment to those responses. T-cell graft biodistribution data 
did not support a hypothesis where the outcome of the therapies could be solely explained by trafficking. A 
major limitation of this technique could arise from the intratumoral proliferation of infiltrated radiolabeled T-
cells. For example, the percentage of the initially injected dose measured by SPECT/CT would be the same 
regardless of whether T cells newly arrived to the tumor would remain non-proliferative or expand several 
rounds. Because the radioactivity inside cells cannot increase, a non-proliferative cell would give the same 
absolute radioactive signal as the sum of e.g. 8 cells resulting  from 3 rounds of mitosis of the initial cell, while 
the actual amount of T-cells is 8 times higher (Supplementary figure 4). Still, taking this possibility into account, 
the values and significances from the early time points in the biodistribution assay do not endorse trafficking as 
the main  mechanistic explanation on why the tumors treated with oncolytic adenovirus respond better to 
adoptive T-cell therapy than other groups. It is also relevant to emphasize that the trafficking of endogenous T 
cells to the tumor was not measured, and that can play an important role in terms of antitumor efficacy. 
Moreover, we did not measure possible de novo adaptive responses, also known as epitope spreading, which 
are known to occur following adenovirus injection into tumors
51
. 
Investigating expression levels of immunologically relevant genes from tumors complements the T-cell graft 
trafficking data. Previous studies highlighted the ability of adenoviruses to engage successfully with the 
immune system, in particular with the T-cell compartment57-59. Following those ideas, the results presented in 
this study show how adenovirus – uniquely among the studied viruses - triggers a wide immunostimulatory 
response. Genes upregulated by treatment related to innate immunity elements (TLR9, TLR2), myeloid cell 
markers of activation (CD80, CD40), lymphocyte markers (CD3E, CD4) and their cytotoxic effector components 
(GZMM), diverse extracellular and intracellular messengers of immune stimulation (IL1B, TNF, IFNGR1, HCK, 
SYK) and proinflammatory chemokines for the attraction of lymphocytes (CCL3) and macrophages (CCL4). This 
molecular network points to a circumstance where it is very likely that innate immunity promotes an eventual 
appearance of adaptive immunity against the tumor. In this sense, the use of oncolytic viruses seem to have a 
broad effect in the tumor microenvironment that include not only interactions with the T-cell compartment of 
the immune system but a diverse number of cell types. Dissecting the effect of the virus on the different cell 
types in the tumor would be a way to study further the mechanism on how oncolytic viruses can enhance T-cell 
therapies. 
The study of the whole tumor expression patterns was relevant to understand the overall situation at the 
tumor although it would be valuable to have a deeper understanding on the contribution of those changes 
specifically by different cell types (i.e. tumor cells, dentritic cells, T cells, etc)). 
In addition, we saw upregulation of ARG1, which codes for arginase, an enzyme that attenuates T-cell activity
60
. 
The induction of ARG1 can be a homeostatic response to balance the upregulation of the other 15 
immunostimulatory genes
61, 62
. One of the limitations of this experiment is that it has been set to a specific time 
point (day 6 after treatment started), which might give an incomplete view of the immune effects triggered 
earlier or later. However, day 6 should be an adequate time point to study the coexistence of both innate and 
adaptive immune processes, as adaptive responses usually take 4-7 days to be developed. These results go in 
line with previous work by others
63-65
, where they show importance of having a favorable tumor 
microenvironment that supports antitumor immune responses. 
Modern oncolytic virotherapy is gaining relevance as a therapeutic approach due to the possibilities it offers in 
terms of immune modulation. Several oncolytic viruses that are currently under clinical and preclinical 
development are engineered to express immune mediators, such as cytokines, immune ligands or antagonists. 
TILT-123 is a 5/3 chimeric adenovirus, designed specifically to enable the T-cell compartment of the immune 
system
52
. Because adenovirus performed better than the other viruses as a T-cell enabler, it was particularly 
attractive to compare the treatment outcome with an adenovirus engineered to enhance specifically such a cell 
population. The arming device had a positive impact on reducing tumor size, increasing antitumor specific 
memory and increasing T-cell trafficking towards the tumor. Interestingly, there was less significant 
upregulation of immunostimulatory genes as compared with the unarmed adenovirus, as previously described 
by Havunen et al
56
. In addition, treatment induced some immunosuppressive genes, such as IL-10, which again 
might be a homeostatic response.  
Reovirus and herpes simplex virus showed the fastest direct oncolysis of tumor cells but deliveredsub-
significant tumor microenvironment modifications, which, if reinforced or optimized, could end up improving 
the overall outcome of the therapy. Vaccinia seemed to have a less visible impact at the immunological level, 
maybe because even if tumor selective, it is a virus naturally armed with a considerable armamentarium for 
immune evasion66, 67. Another possibility for the absence of changes in the immune microenvironment after 
some of the viruses is that the intrinsic tumor immune suppressivity could dampen the signals produced by 
those viruses and only the most potent ones would be able to overcome that suppressivity threshold. 
Nevertheless, vaccinia viruses together with herpes simplex viruses have the largest genome space for the 
insertion of transgenes. Thus, comparison of viruses armed with immunostimulatory molecules could yield 
different results. Another layer of complexity is added when taking into account that different viruses have 
faster or slower oncolytic cycles, which affects both immunogenicity and direct tumor cell killing.  
An important issue regarding the use of oncolytic viruses is the length of treatment. In the case of the 
comparison between armed and unarmed adenovirus it seems that as long as the therapy was ongoing, a 
higher proportion of tumors were under control with TILT-123 treatment. When the therapy was discontinued, 
survival decreased to a similar level as with the unarmed group. One interpretation of this phenomenon could 
be linked to the fact that the virus is designed to express the transgenes only while the virus is actively 
replicating
52
. If tumor fate is still undecided in terms of antitumor vs protumor forces, having ongoing cytokine 
production there might play an important role that is ablated as soon as the virus is cleared. This would not be 
the case for other sources of antitumor effects, such as the immune responses generated after the oncolytic 
cycle. It can be argued that long term dosing could be required in clinical trials using viruses with an arming 
device.  This approach was employed in a Phase 3 trial with Talimogene laherparepvec, when treatment 
continued for up to 18 months if efficacy is seen
68
. Another rationale supporting the multiple administration of 
the virotherapy relates to the fact that as antiviral immunity builds up, it reduces the persistence of the virus 
but it can be helpful to boost immune activity inside the tumor
69
. In summary, armed and unarmed 
adenoviruses appear appealing for enabling T-cell therapy. 
This study did not intend to compare the direct oncolytic activity of the different viruses, but instead how they 
could be used in the context of T-cell therapy. For the use of oncolytic viruses to enable other types of 
therapies, a different experimental design would be required. In this study’s specific context, oncolytic 
adenoviruses seemed the strongest candidate among those tested. Higher antitumor effects correlated with 
changes in the tumor microenvironment. Interestingly, modification of the microenvironment appeared more 
important than effects on T-cell trafficking. The results also make evident the opportunities arising from 
oncolytic viruses interacting with the immune system to favor antitumor responses. Tailoring a T-cell specific 
arming device in an adenovirus (such as TNFa and IL-2 used here), can help improve the immunostimulatory 
capacities of these viruses even further. TILT-123 is now being studied in melanoma patients receiving a TIL 
therapy (NCT04217473).  
 
Materials and Methods 
- Oncolytic viruses 
Oncolytic viruses from four different virus families were included in this study: Ad5/3-E2F-d24 (Adenoviridae), 
VVtd-tomato (JX-929 strain) (Poxviridae)
70
, HSV-1 (17+)Lox-PmCMVGFP (Herpesviridae, a kind gift from Beate 
Sodeik, Hannover Medical School, Germany)
71, 72
 and Pelareorep (Reolysin®) (Reoviridae, a kind gift from 
Oncolytics). An engineered version of the adenovirus candidate (Ad5/3-E2F-d24-hTNFa-IRES-hIL2, A.K.A. TILT-
123) was also used in the experimental phase. Intratumoral administration of the viruses in 50 µl of PBS (or PBS 
alone in the control groups) was performed by direct injection with 30G insulin needles according to the 
schedule established for each experiment. 
 
- Animal and tumor model 
Male Syrian hamsters (French colony) were used as an animal model for the in vivo experimentation. They 
were obtained as 4-6 week old from Charles River Laboratories (Wilmington, Massachusetts, USA).  Syrian 
hamster model was selected to study in vivo efficacy, as it is one of the few models permissive for the 
replication of all of the viruses used in the study
42-45
. The tumor model selected is the syngeneic HapT1 
pancreatic carcinoma as it allows growing tumor infiltrating lymphocytes (TILs) ex vivo, to be used as a model 
for adoptive cell therapy (ACT). A syngeneic pancreatic carcinoma cell line (Hap-T1) was used to studying the 
antitumor efficacy of the treatments in the study. For that purpose, 2 x 10
6
 cells were subcutaneously delivered 
into the lower lateral flank(s) of the hamsters. 5-6 days later, when tumors were palpable and measurable, 
they started receiving treatments. Animals, whose tumors surpassed the maximum tolerated tumor 
dimensions, were euthanized and marked as dead. Animals developing ulcers were marked as censored in 
survival studies and euthanized. When studying antitumor memory, those animals showing complete 
responses from the originally engrafted tumor (lower right flank) were rechallenged with 2 x 10
6
 HapT1 cells in 
the upper left flank and 2.5 x 10
5
 DDT1-MF2 (syngeneic leiomyosarcoma cell line) in the upper right flank to 
evaluate the specificity of the antitumor memory. For the tumor volume records, a digital caliper was used to 
measure tumor dimensions and transformed into volume by using a standardized formula (0.5 x longest 
diameter x shortest diameter
2
).  
 - Adoptive cell therapy treatments 
Tumor-infiltrating lymphocytes (TILs) were generated out of HapT1 tumors and used as adoptive cell therapy 
graft as described before
46
. Briefly, HapT1 tumor were grown until they reach a diameter close to 20 mm. At 
that point, tumors are harvested and cultured in immunostimulatory conditions (IL-2 and Concanavalin A) to 
expand the TILs present in the tumor. After expansion, T cells are collected, and 4 x 10
7
cells are 
intraperitoneally administered to the animals on what is considered day 0 of the experiments. 
 
- Biodistribution analyses 
TILs were labeled with 
111
In-oxine as described earlier and administered intraperitoneally into Syrian 
hamsters
56
.  The injected dose was 4.82 ± 0.72 MBq. The hamsters were bearing two HapT1 tumors (n = 3-
4/group). Animals were imaged with NanoScan SPECT/CT (Mediso, Budapest, Hungary) at 24, 72, and 144 
hours after the administration of the radiolabeled cells. For in vivo measuring of the TIL trafficking and 
accumulation, tumors were delineated by using the co-registered CT images. The results were calculated as 
percentage of activity in the tumor from the injected dose. Corresponding values from the biodistribution data 
at day 6 were divided by the tissue mass (g). On day 6, tumors were harvested after in vivo imaging and the 
radioactivity was measured ex vivo by a gamma counter (Wizard 3, Perkin Elmer, Waltham, Massachusetts, 
USA) for validation. Similarly, CT-defined tumor volumes were correlated with ex vivo mass to validate the 
approach. Other tissues such as blood, kidney, spleen, and muscle were also harvested for ex vivo 
measurement of radioactivity.  
 
- Gene expression analyses 
Tumors harvested during in vivo experimentation were stabilized in RNAlater (R0901, Sigma-Aldrich, St. Louis, 
Missouri, USA) and stored at -20ºC. RNA was purified from those tumors following RNeasy (74104, Qiagen, 
Hilden, Germany) kit manufacturer’s guide. Total RNA concentration was measured in all the samples with a 
Biophotometer (Eppendorf, Wesbury, New York, USA) to ensure the presence of sufficient RNA concentration. 
For quantitative assessment of the expression of 96 genes, we designed a custom nCounter panel (NanoString 
technologies, Seattle, Washington, USA) that was run for the samples as indicated by manufacturer. Data 
analysis was performed by Nanostring’s Data Analysis service (single blind analysis) where normalization of 
gene expression based on housekeeping genes was performed. Quality control check-ups were performed for 
all the samples and all the target genes included in the panel. Differential expression in genes between 
oncolytic virus treated tumors versus PBS treated tumors was represented in volcano plots based on the 
significance and fold change for each gene.  
 
- Oncolytic activity measurements 
HapT1 cells were cultured in vitro up to 14 days in the presence of the above mentioned viruses at different 
concentrations. The concentrations used are relative to the viral doses described before. Cell viability was 
assessed with Cell Titer 96 AQueous One Solution Cell Proliferation Assay (G3582, Promega, Madison, 
Wisconsin, USA), following manufacturer indications. The viability of mock-treated cells was set to 100%. 
 
- Statistics 
SPSS Statistics 25 software (IBM, Armonk, New York, USA) was used to perform a mixed-model analysis for 
tumor growth evolution based on the tumor volumes (logarithmic transformation of the volumes normalized 
on day 0 volumes) as described before73. GraphPad Prism 8 (GraphPad Software, San Diego, California, USA) 
was used for log rank Mantel-Cox test on Kaplan-Meier survival curves, Pearson’s r, linear regression, as well as 
the graphic representation of the data. P values under 0.05 were considered statistically significant 
 
- Ethical statement 
Based on the recommendations included in the Act on the Protection of Animals Used for Scientific or 
Educational Purposes (497/2013) and the Government Decree on the Protection of Animals Used for Scientific 
or Educational Purposes (564/2013) as well as the European Directive 2010/63/EU, experimental protocols and 
procedures were established and then approved by the ethical committee of the Animal Experimental Board 
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Figure information 
Figure 1. Antitumor efficacy after the use of different oncolytic viruses to enable T-cell therapy. (A) 
Experimental design: forty-one Syrian hamsters carrying subcutaneous HapT1 tumors were randomized into 
groups and treated with TILs intraperitoneally, and PBS or one of the studied viruses intratumorally. After the 
treatment period, the animals were followed up to day 250. (B-F) Individual normalized tumor volume lines for 
the different groups (n=8-9). Tumor size at the beginning of the treatments was set to 100% (Mixed model 
analysis, ***p<0.001). (G) Overall survival of the treated animals. (Kaplan-Meier, Log rank Mantel-Cox test; 
*p<0.05). 
 
Figure 2. Study of antitumor memory in complete responders. (A)Experimental design: animals treated with 
ACT and different oncolytic viruses (or PBS) experiencing complete responses were rechallenged with HapT1 and 
challenged with DDT1-MF2 to study antitumor specific memory (no additional treatments given). In addition, 
naïve animals were simultaneously engrafted with HapT1 and DDT1-MF2 tumors. (B) Groups included in the 
experiment: Naïve animals group (n=3), PBS + TILs group (n=1), Adenovirus + TILs group (n=5), Vaccinia + TILs 
(n=1) and Reovirus + TILs (n=1). The number of animals depended on how many had been cured in the first part 
of the experiment. (C) Mean tumor volumes for the HapT1 tumors. (D) Mean tumor volumes for the DDT1-MF2 
tumors. 
 
Figure 3. Tracking of systemically administered TILs after oncolytic virus intratumoral injection. (A) 
Experimental design: thirty-four Syrian hamsters carrying subcutaneous HapT1 tumors were randomized into 
groups and treated with 
111
Indium labelled TILs intraperitoneally, and PBS or one of the studied viruses 
intratumorally. During the experiment, animals were imaged with SPECT/CT to quantify the biodistribution of 
the injected TILs. At the end of the experiment, animals were euthanized and different organs were harvested 
for ex vivo 
111
Indium measurement or, in the case of tumors also for multiplexed RNA sequencing. (B) 
Normalized tumor volumes for the different groups (n=6-8). (C) Correlation between tumor volumes measured 
using CT and the weight of those tumors after they were harvested. (D) Correlation between the in vivo 
radiation signal measured with SPEC/CT and the ex vivo samples measured by gamma counting. (E) TIL-
associated radiation of tumors measured in vivo with SPECT/CT on days 1, 3 and 6. (F) TIL-associated radiation 
measured ex vivo on different tissues by gamma counting on day 6 (*p<0.05; **p<0.01). 
 
Figure 4. Impact of different oncolytic viruses in the tumor microenvironment. Comparisons were made 
between RNA expression profiles from the different virally treated groups vs PBS treated group. Viral treatment 
used in the group compared to PBS treated animals: (A) Adenovirus. (B) Vaccinia Virus. (C) Herpes simplex virus. 
(D) Reovirus. The plots indicate the names of those genes for which there is a statistically significant difference 
(adjusted p value <0.05) and an expression change of at least double or half compared to reference group (-
1>Log2 fold change>1).  
 
Figure 5. Antitumor and immunological effects of arming an adenovirus with immunostimulatory cytokines. 
(A) Summary of unarmed and armed virus constructs. (B) Grouped normalized tumor volume values for the 
different groups (n=6-9 per group) after receiving TIL therapy (intraperitoneally) and virotherapy or PBS 
(intratumorally). Treatment schedule is presented in Figure 1A. (C) Overall survival data. Gray dashed line marks 
discontinuation of the treatments. (D) Mean tumor volume at day 19 after HapT1 rechallenge in complete 
responders from HapT1 tumors. (E) Mean tumor volume at day 19 after DDT1-MF2 challenge in complete 
responders from HapT1 tumors (Naïve n=3, PBS+TILs n=1, Adenovirus+TILs n=5, TILT-123+TILs n=2). (F) 13 
Syrian hamsters carrying subcutaneous HapT1 tumors were randomized into groups and treated with 
111
Indium 
labelled TILs intraperitoneally, and with PBS (n=4), unarmed adenovirus (n=5), or armed adenovirus (n=4). At 
day 6 of the experiment, tumors were harvested for ex vivo 
111
Indium measurement by a gamma counter 
(*p<0.05). Comparisons were made between the RNA expression profiles from each of the two adenovirus 
treated groups vs PBS treated group. Animals carrying these tumors were treated as described in Figure 3A. 
Viral treatment used in the group compared to PBS treated animals: (G) Adenovirus. (H) TILT-123. The plots 
indicate the names of those genes for which there is a statistically significant difference (adjusted p value <0.05) 
and an expression change over double or below half to those in the reference group (-1>Log2 fold change>1).  
 
 
Tables  
VIRUS REFERENCE YEAR 
MAXIMUM DOSE 
(HUMAN) 
EXTRAPOLATED 
DOSE 
(HAMSTER) 
ADENOVIRUS Small EJ 
48
 2006 6 x 10
12
 vp 8 x 10
9
 vp 
VACCINIA Zeh HJ 
49
 2015 3 x 10
9
 pfu 4 x 10
6
 pfu 
HERPES SIMPLEX Andtbacka RH 
47
 2015 4 x 10
8
 pfu 5.3 x 10
5
 pfu 
REOVIRUS Karapanagiotou EM 50 2012 3 x 1010 TCID50 4 x 10
7 TCID50 
Table 1. Viral dose extrapolation according to maximum tolerated doses in humans. vp; viral particles. pfu; 
plaque forming units, TCID50; median tissue culture infectious dose. 
 
List of Changes after Reviewers comments 
 
Reviewer #1 (Remarks to the Author): 
 
This is a convincing manuscript that provides critical data supporting viro-immune therapy of 
cancer. The studies were done in an adequate hamster model and employ state-of-the art 
techniques to document the oncolytic and immune-stimulatory effects of adenovirus, vaccinia virus, 
herpes simplex virus, and reovirus in combination with adoptive T-cell therapy. A critical caveat of 
such a comparative study, i.e. selecting the treatment dose for the different viruses, has been 
addressed satisfactory. 
 
Minor comments: 
-Figure 1: Viruses were injected every three days until day 39. Please comment on the effect of 
developing adaptive immune responses against the virus on anti-tumor efficacy of the treatment. 
The impact of antiviral immune responses was added into the discussion: 
“Another rationale supporting the multiple administration of the virotherapy relates to the fact that 
antiviral as antiviral immunity builds up, it reduces the persistence of the virus but it can be helpful to boost 
immune activity inside the tumor”. 
 
-Please discuss the relevance of the approach for metastatic disease, when only selected tumor 
lesions can be injected with oncolytic virus. 
It has been included a sentence (and its respective references) regarding the relevance of the 
approach on uninjected lesions and metastatic disease. 
“Other studies focused on the systemic effect after the use of oncolytic adenoviruses and T-cell therapies 
showing that metastastatic proceses can be avoided and that uninjected established tumors benefit from 
the treatment.”  
 
-Please provide references for successful anti-PD1 CAR-T therapy. 
References including the success of CAR T-cell therapy and anti-PD-1 were added into the first 
paragraph of discussion.  
 
 
 
Reviewer #2 (Remarks to the Author): 
 
Authors compare four different oncolytic viruses in terms of antitumor activity when combined with 
TIL therapy against one immune-competent hamster tumor model. The idea of comparing different 
oncolytic viruses is seldom presented in papers and if properly done would direct clinical research 
toward the most effective virus type.In general terms although the concept is really relevant, a 
sound conclusion in favor of one virus type against the others would require research in different 
conditions and models.  
 
Although the authors discuss that they did not intend to compare the direct oncolytic activity of the 
four viruses but how they behave in the context of T-cell therapy, a virus-alone immunotherapy 
should be the basis to further explore combination immunotherapies (such as the TIL-virus combo 
presented in the current paper). One hamster tumor model (HapT1) is selected based on a 
putative replication permissiveness to the four viruses. It would be nice to see a comparison of 
such permissiveness in vitro, and also to study the supposed intratumoral virus replication in vivo. 
A central question remains as to whether replication is needed at all, in particular when so many 
intratumoral injections are performed. Replication in tumors is not evaluated. Although the main 
aim is not to compare oncolytic activity, this parameter should be investigated to understand the 
results. 
Direct oncolysis ability from all the viruses was studied on HapT1 cells. A new figure was created 
(supplementary figure 1), and two graphs were added to supplementary figure 3. Results text 
description for figure 1 was also amended to include the new data: 
“The selected tumor model, HapT1 pancreatic carcinoma, enables the isolation of tumor infiltrating 
lymphocytes (TILs) for ex vivo amplification, for use as an adoptive cell therapy (ACT). It was also 
assessed how the different viruses have different oncolytic dynamics on this cell line, even if all of 
them showed complete tumor cell lysis by day 14 (Supplementary figure 1).” 
 
 
Supplementary figure 1. Oncolytic capability of the viruses. HapT1 cells were cultured with three 
concentrations of viruses extrapolated from in previously described treatments (using each virus standard 
units) and cell viability was measured at days 3, 6, 11 and 14. (A) Adenovirus: 10
2
, 10
3
 and 10
4
 vp/cell. (B) 
Vaccinia virus: 5*10
-2
, 5*10
-1 
and 5 pfu/cell. (C) Herpes simplex virus: 7*10
-3
, 7*10
-2 
and 7*10
-1 
 pfu/cell. (D) 
Reovirus: 5*10
-1
, 5
 
and 5*10
1
 TCID50/cell. 
 
 
Supplementary figure 3. Impact of the TNFa and IL-2 arming deviceon oncolytic activity and  gene 
expression. (A-B) HapT1 cells were cultured with three concentrations of both adenoviruses and cell viability 
was measured at days 3, 6, 11 and 14. 10
2
, 10
3
 and 10
4
 vp/cell of each virus was used. 
This data was generated to check that the viruses are able to trigger oncolysis on HapT1 cells and 
to understand if there are differences in the lysis kinetics between viruses. Further studies (refs 42-
45) on the use of those viruses in vivo in solid tumor models strengthen the conclusion.  
Going deeper into the question of the relevance of multiple administration of the virus was not 
something we focused in on this paper as it is generally accepted in the field, even in clinical 
practice with talimogene laherparepvec that multiple administration is beneficial for the treatment’s 
outcome. In addition, other possible benefits of the multiple administration scheme might rely on 
the antiviral immunity boosting the antitumor one. A study trying to challenge single vs multiple 
oncolytic virus administration should be thorough and probably an article by itself. Discussion was 
added with ideas about this topic: 
“Another rationale supporting the multiple administration of the virotherapy relates to the fact that 
antiviral as antiviral immunity builds up, it reduces the persistence of the virus but it can be helpful 
to boost immune activity inside the tumor” 
 
Of course, the relevance of the results would increase if more than just one model is tested. Other 
hamster tumor cell lines have been reported to be permissive to adenovirus. 
While we understand the benefits of adding more models and more cell lines, we were not able to 
confirm adenoviral replication from additional models for which there are also available TIL 
production possibilities. 
Even for Syrian hamster tumor models, creation of a TIL graft of quality is challenging and only 
optimized to our knowledge for HapT1 (Siurala M et al. Oncoimmunology 2016) while other tumor 
models failed to provide meaningful results.  
 
Another parameter is the genetic modifications in the compared viruses. In this paper vaccinia 
seems to have tomato fluorescent protein and herpes seem to express GFP, compared to 
adenovirus and reovirus which are devoid of transgenes. Could this affect the results? 
The use of bioluminescent tags such as the tomato fluorescent protein and GFP, has been widely 
tested in different vectors and models without noticeable impact in their functionality. Their lytic 
ability could be affected if the cloning of the fluorescent tags would be incorrect but the new 
Supplementary figure 1 is the evidence that they are still fully replicative (besides the fact that it 
has been used by our collaborators, the ones that created those viruses). 
A different discussion would be to around the topic of the immunogenicity of those fluorescent 
proteins. While some studies showed that those proteins are immunogenic and can cause adaptive 
immune responses against GFP+ or tomato fluorescent protein+ cells, in this study we don’t see 
major immunogenic processes developing in those groups. As they are the groups with the lower 
modifications in gene expression, we do not think hypothetically less immunogenicity (by removing 
the fluorescent tags) would change the results in the comparison of the viruses. 
 
 The adenovirus selected has the chimeric 5/3 capsid. How does this compares to the unmodified 
capsid? 
Different adenovirus serotypes have been used both preclinically and clinically (Koski, A., et al. 
2013 Human Gene Therapy, Cervera-Carrascon V et al. 2019. Expert opinion in biological 
therapy).  
As mentioned in previous comments differences could be expected from different viruses, but we 
understand that 5/3 serotype is one relevant candidate to study in the scope of the present study. 
Furthermore, the comparison between 5/3 serotype versus purely 5, are likely to be minimal under 
the experimental conditions used as the model is only semi-permissive to adenoviruses. 
 
 Are the results only applicable to the four particular viruses studied, and in only the HapT1 model, 
and only when combined with TIL therapy? 
About the concerns regarding the presence of one model only, those were replied in the reviewer 
question #3 (“Of course, the relevance of the results would increase if more than just one model is 
tested. Other hamster tumor cell lines have been reported to be permissive to adenovirus.”). 
Yet again, we understand the point that testing more viruses and not only the particular ones would 
help to have a broader view on the topic but having representative viruses from four different virus 
families gives a sense on how different virus related biologies impact the ability to enable immune 
responses. 
Regarding TIL therapy, it comes back again to the fact that HapT1 is the only suitable model to 
generate TILs. There are no CAR T cell therapies or Checkpoint inhibitors for Syrian hamster, so it 
is not possible to test further alternatives of T cell therapies. 
 
Why the MTD is taken from studies where the injection route is different (systemic for adenovirus 
and reovirus vs intratumoral for herpes and vaccinia)? 
The maximally tolerated dose for each virus was chosen regardless of the route of administration 
as the extrapolated doses were going to be tested with a 10 fold increase and a 10 fold decrease 
for a confirmation that the dose/effect had reached plateau (Supplementary figure 2). 
In those confirmatory studies we saw how for all the viruses, a 10 fold increase did not produce an 
improved outcome in terms of antitumor efficacy. That finding, together with the daily check-up on 
the health of the animals were no visible side effects were assessed after the treatments, allowed 
us to support the doses selected. 
 Supplementary figure 2. Assessment of the dose-effect differences for different oncolytic viruses. 39 
Syrian Hamsters engrafted with bilateral subcutaneous HapT1 tumors were randomized and assigned to 
different groups treated intratumorally with PBS or different oncolytic viruses at different doses (L; 0.1x 
extrapolated dose. E; 1x extrapolated dose. H; 10x extrapolated dose). Each group comprised 6 tumors. 
Mean normalized tumor volume for each group is shown (with SEM). The grey dashed line represents mean 
normalized tumor volume for a negative control group. 
 
Do TILs alone (intraperitoneally administered) provide any therapeutic effect compared to no 
treatment? 
Development of TIL therapy for this specific model have been developed (Siurala M et al. 2016. 
Oncoimmunology) and repeatedly tested, showing limited antitumor efficacy (see snip below from 
Santos JM et al. 2016. International Journal of Cancer) 
 
 
Is the multiple intratumoral injection (every three days) effective? (Produced NAbs preclude 
intratumoral infection?) 
Besides the comments provided to the reviewers comments on point #1 (“A central question 
remains as to whether replication is needed at all, in particular when so many intratumoral 
injections are performed”), it is highly likely that the administration of the viruses triggers generation 
of adaptive responses against the viruses themselves. As the multiple administration is given at the 
same time, we do not believe this would be a point to change the endpoint result of the 
comparisons. 
From a different angle, the impact of antiviral has also been understood as a factor with a positive 
outcome arising from oncolytic virotherapy in the sense that antitumor responses will be indirectly 
boosted when the tumor microenvironment (Ricca JM et al. 2018. Mol Ther, Li X et al. 2017. Clin 
Can Res). 
Considering this information, we decided to focus on the comparison of the viruses using the same 
scheme rather than trying to optimise regimen of administrations of different viruses. 
 
Rechallenging results (Fig2) for vaccinia and reovirus were based on one animal (and none for 
herpes) and as mentioned no conclusions can be drawn. However it would be really of interest to 
know if these viruses induce antitumor immunity. The same very limited number of animals applies 
to the rechallenging experiment with TILT123 (Fig5). 
As the reviewer acknowledged, we are not drawing conclusions regarding the statistical 
significance of the rechallenging experiments with a low number of subjects. On the other hand, 
the low number of animals that showed complete responses from the initial tumor is informative on 
the whole efficacy of the treatment. 
Even if it would be interesting to have a deeper understanding on the antitumor memory for those 
groups and have significant results, the amount of animals per group should be around 40-50 to 
end up with 5-6 complete responders. Following those indications will result in an animal 
experiment with 250 animals, which is considerably demanding. 
Similar studies regarding adaptive memory of adenovirally treated tumors have been shown in 
other studies (Havunen R et al. 2018. Mol Ther Oncolytics). 
 
The T cell biodistribution study (Fig 3) would have been more informative if T cells had been 
labeled with a tracer that can be seen in tissue (tumor) sections (several fluorescent tracers are 
available for this) and an in situ biodistrubution had been studied.  
The use of radioactive tracers required for in vivo tracking of the TILs transferred to the animals 
made logistically challenging many subsequent analyses of the tumors ex vivo. As each virus could 
have effects on T cell biodistribution at different times, in this study we considered more 
informative to have multiple measurements of the T cell biodistribution rather than having an ex 
vivo evaluation at a particular time point. 
 
It is really intriguing that multiple injections of herpes, vaccinia or reovirus intratumorally do not 
induce significant changes of intratumoral gene expression of inflammatory genes and other innate 
immune genes (Fig 4, and suppl table 2, with vaccinia even not sub-significant changes). One 
would expect that a virus in a tumor induces some inflammatory changes. Does this match with 
results described for those viruses? Has this been corroborated in multiple experiments? 
Results from Figure 4 have been confirmed in two different experiments. Statistical analyses of the 
gene expression were performed blindly by the Data analysis team at Nanostring. and even if one 
would expect significant inflammatory changes after oncolytic virus administration the significance 
is not present with this sample size. With this sample size we could not obtain significance for 
those viruses but most likely with a higher n, statistical significance would be achieved.  
In this sense, we consider informative that at the current sample size adenovirus shows multiple 
significant upregulations while the other viruses do not. Those kind of observations are the whole 
point of the study as what we are aiming to compare the viruses with each other. We do not claim 
that Herpes simplex viruses or Vaccinia viruses do not cause inflammation but with the current 
data we can just conclude that Adenovirus achieves it better. 
We did not intend to go deep on the biology of each virus to try to explain the results but for 
example poxviruses (such as Vaccinia virus) as mentioned in discussion: 
“Vaccinia seemed to have a less visible impact at the immunological level, maybe because even if 
tumor selective, it is a virus naturally armed with a considerable armamentarium for immune 
evasion”. 
 
 
Reviewer #3 (Remarks to the Author): 
 
Major comments: 
1. Although the authors found that combination with Onc.Ad and TILs had the best anti-tumor 
effects among Onc.Vs tested in this study, they did not address their overall hypothesis that Onc.V 
can improve the utility of adoptive T-cell therapy because they injected Onc.Vs every 3 days up to 
day 40 (15 times) in contrast to single TIL infusion at day 0. To better address their stated 
hypothesis, the authors should evaluate/compare the anti-tumor effects of injections of Onc.Vs 
prior to TIL infusion as in their prior study (Molecular Therapy Oncolytics 2017). 
An alternative and interesting approach for the regimen of administration would be as proposed in 
this comment when a number of OV treatments would be given prior to the adoptive cell transfer. 
In our 2017 study, we used such approach only Adenoviruses, but as it was the only virus used 
there we don’t know if the same conclusions could be extrapolated for other viruses. There is the 
possibility that different viruses would have different optimal regimen of administrations. As the 
regimen of administration presented in this manuscript is the same for all the viruses we think it is a 
fair approach.   
 
2. Following the above, since the authors stated that Onc.V treatments induce immunostimulatory 
signals and reverse immunosuppression, the authors should address how these Onc.V treatments 
change the cytokine/chemokine profile of tumors as well as the tumor microenvironment (immune 
cell infiltration) prior to TIL infusion. 
Having an understanding on how these different viruses affect the tumor without the TIL infusion 
would be of relevance but the present work aims to understand this phenomenon in the specific 
context of T-cell therapy. For that purpose it is stated in discussion that: 
“…this study focuses in a direct comparison of some of the most relevant candidates in the context 
of TIL therapy.” 
 
3. If authors aim to compare the direct impact of Onc.V treatments on adoptively transferred TILs, 
they should isolate adoptively transferred TILs (e.g., tagged with EGFP) and profile their RNA 
expression, especially in the experiment directly comparing Unarmed Onc.Ad to TILT-123. 
The use of oncolytic viruses to enable TILs is a process most likely enabled by a wide range of 
effects triggered in the tumor, including direct effects on TILs but not exclusively. In this sense, the 
interaction of the viruses with the microenvironment can be as critical or even more to TIL 
functionality that the direct interaction between viruses and TILs. Even if we prioritized on the 
overall changes in the tumor,  
“the use of oncolytic viruses seem to have a broad effect in the tumor microenvironment that 
include not only interactions with the T-cell compartment of the immune system but a diverse 
number of cell types. Dissecting the effect of the virus on the different cell types in the tumor would 
be a way to study further the mechanism on how oncolytic viruses can enhance T-cell therapies.” 
 
Minor comments: 
1. In the Abstract and Discussion, the authors mention that a clinical trial ongoing with combination 
of adoptively transferred TILs and TILT-123, but there is no NCT number in manuscript. The 
authors should provide NCT number. 
NCT number from clinical trial is now included in the text where it is mentioned. 
“A clinical trial is ongoing, where patients receiving TIL treatment also receive TILT-123 
(NCT04217473).” 
“TILT-123 is now being studied in melanoma patients receiving a TIL therapy (NCT04217473).” 
 
2. In the Introduction, the history of viruses for cancer treatment (first paragraph) is redundant. The 
authors can remove this paragraph and emphasize how other groups (University of Pennsylvania, 
Baylor College of Medicine, IDIBELL) combine Onc.Vs with T-cell therapy to improve adoptively 
transferred T cell activity. 
Paragraph 1 has been edited to avoid redundancy. 
References including international efforts using oncolytic viruses to enable T-cell therapies were 
added in the last paragraph of introduction. 
 
3. The authors should clarify that adoptively transferred T-cell therapies have succeeded in 
patients with hematologic malignancies but have had limited success in patients with solid tumors. 
The current statement in the manuscript misleads readers, and these sentences should be 
changed. 
Modifications in the text were performed following reviewer’s indications. 
“The implementation of immunotherapies such as checkpoint inhibitors and various immune-cell 
therapy based platforms has mediated a therapeutic revolution in oncology. At the same time, 
there is clear room for improvement as the patients responding to immunological treatments are 
still the minority, with some exceptions (e.g. CAR T therapies in some hematological malignancies 
or anti-PD1 in selected indications).” 
 
4. The authors should evaluate whether Onc.V agents tested in this manuscript similarly infect and 
lyse HapT1 cells in vitro and put that result in Fig. 1. 
 
A new figure was created after the study of the direct lytic capability of the different viruses used in 
the rest of the manuscript. Those results have been included as a separate new figure and not as 
part of Figure 1 as it could mislead the reader. 
 
While the new figure relates to the direct lytic ability of each virus in vitro, figure 1 describes the 
method to calculate the dose after the maximum doses used in vivo (in humans). For that reason 
we believe it is more adequate to have figure 1 for dose calculation and supplementary figure 1 as 
a test on how different viruses have different oncolytic velocities. 
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